Back to Depression And Anxiety
NCT01715805
NCT01715805
Who may be able to join
Who might be able to join this trial:
- You have given your written agreement to take part before any trial procedures begin
- You have been diagnosed with Major Depressive Disorder (a serious form of depression) according to a standard set of medical guidelines called DSM-IV-TR
- You score at least 20 out of a possible 52 on a standard depression rating scale called the Hamilton Depression Scale (HAMD-17), measured at two separate visits (this scale is used by doctors to measure how severe depression symptoms are)
Who may not be able to join:
- You do not meet the standard medical guidelines (DSM-IV-TR) for a diagnosis of Major Depressive Disorder
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Forest Laboratories
Registry
clinicaltrials_gov
Start date
15 November 2012
Est. completion
24 June 2016
Where this trial is recruiting
Puerto Rico
🇺🇸 United States
Primary endpoints
Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period; Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind Period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.